Literature DB >> 34424190

Continuing Cardiopulmonary Symptoms, Disability, and Financial Toxicity 1 Month After Hospitalization for Third-Wave COVID-19: Early Results From a US Nationwide Cohort.

Theodore J Iwashyna1,2, Lee A Kamphuis2, Stephanie J Gundel3, Aluko A Hope4,5, Sarah Jolley6, Andrew J Admon1, Ellen Caldwell7, Max L Monahan2, Katherine Hauschildt2, B Taylor Thompson8, Catherine L Hough5.   

Abstract

BACKGROUND: Patients discharged after COVID-19 report ongoing needs.
OBJECTIVES: To measure incident symptoms after COVID-19 hospitalization. DESIGN, SETTING, AND PARTICIPANTS: Preplanned early look at 1-month follow-up surveys from patients hospitalized August 2020 to January 2021 in NHLBI PETAL Network's Biology and Longitudinal Epidemiology: COVID-19 Observational (BLUE CORAL) study. English- or Spanish-speaking hospitalized adults without substantial pre-COVID-19 disability with a positive molecular test for SARS-CoV-2.
RESULTS: Overall, 253 patients were hospitalized for a median of 5 days (interquartile range [IQR], 3-8), and had a median age of 60 years (IQR, 45-68). By race/ethnicity, 136 (53.8%) were non-Hispanic White, 23 (9.1%) were non-Hispanic Black, and 83 (32.8%) were Hispanic. Most (139 [54.9%]) reported a new or worsened cardiopulmonary symptom, and 16% (n = 39) reported new or increased oxygen use; 213 (84.2%) patients reported not feeling fully back to their pre-COVID-19 level of functioning. New limitations in activities of daily living were present in 130 (52.8%) patients. Financial toxicities, including job loss or change (49 [19.8%]), having a loved one take time off (93 [37.8%]), and using up one's savings (58 [23.2%]), were common. Longer lengths of hospital stay were associated with greater odds of 1-month cardiopulmonary symptoms (adjusted odds ratio [aOR], 1.82 per additional week in the hospital; 95% CI, 1.11-2.98) and new disability (aOR, 2.06; 95% CI, 1.21-3.53). There were not uniform demographic patterns of association. LIMITATIONS: We prioritized patients' reports of their own incident problems over objective testing.
CONCLUSION: Patients who survived COVID-19 in the United States during late 2020/early 2021 still faced new burdens 1 month after hospital discharge.

Entities:  

Year:  2021        PMID: 34424190     DOI: 10.12788/jhm.3660

Source DB:  PubMed          Journal:  J Hosp Med        ISSN: 1553-5592            Impact factor:   2.960


  5 in total

Review 1.  Postacute Sequelae of COVID-19 Critical Illness.

Authors:  Kristin Schwab; Emily Schwitzer; Nida Qadir
Journal:  Crit Care Clin       Date:  2022-01-10       Impact factor: 3.879

Review 2.  Postacute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 Infection.

Authors:  Aluko A Hope; Teresa H Evering
Journal:  Infect Dis Clin North Am       Date:  2022-02-15       Impact factor: 5.905

3.  Disparities in the allocation of inpatient physical and occupational therapy services for patients with COVID-19.

Authors:  Sarah Jolley; Amy Nordon-Craft; Melissa P Wilson; Kyle Ridgeway; Michelle R Rauzi; Jacob Capin; Lauren M Heery; Jennifer Stevens-Lapsley; Kristine M Erlandson
Journal:  J Hosp Med       Date:  2022-02-11       Impact factor: 2.899

4.  Modification of social determinants of health by critical illness and consequences of that modification for recovery: an international qualitative study.

Authors:  Joanne McPeake; Leanne Boehm; Elizabeth Hibbert; Katrina Hauschildt; Rita Bakhru; Anthony Bastin; Brad Butcher; Tammy Eaton; Wendy Harris; Aluko Hope; James Jackson; Annie Johnson; Janet Kloos; Karen Korzick; Judith McCartney; Joel Meyer; Ashley Montgomery-Yates; Tara Quasim; Andrew Slack; Dorothy Wade; Mary Still; Giora Netzer; Ramona O Hopkins; Mark E Mikkelsen; Theodore Iwashyna; Kimberley Haines; Carla Sevin
Journal:  BMJ Open       Date:  2022-09-27       Impact factor: 3.006

5.  Organization of Outpatient Care After COVID-19 Hospitalization.

Authors:  Thomas S Valley; Amanda Schutz; Ithan D Peltan; Kelly C Vranas; Kusum S Mathews; Sarah E Jolley; Jessica A Palakshappa; Catherine L Hough
Journal:  Chest       Date:  2022-01-31       Impact factor: 10.262

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.